secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001104659-23-029405
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23
--------------------------------------------------------------------------------

- Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.
- Net loss $19.1M vs $12.9M in 2021; R&D expense $13.2M; G&A $6.0M.
- NXP800 granted Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian cancer.
- ENGOT and GOG Foundation to lead NXP800 Phase 1b trial in ovarian cancer.
- NXP900 IND submission and Phase 1 start expected first half 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/0001104659-23-029405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/tm238641d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer